Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

Rationale. Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s JA. Aim. To perform health-economic analysis of tocilizumab for subcutaneous and intravenous injections in patients with RA and sJA comparing to TNF-α inhibitors. Materials and methods. Cost-minimizing analysis was used from the perspective of healthcare system (accounting for direct medical costs) with the modelling horizon — 1 year. We included into the model cost of RA and sJA bDMARDs, cost of adverse events correction and costs of laboratory and instrumental diagnostic. Results. Cost minimizing ratio of tocilizumab (subcutaneous form) in RA patients comparing to adalimumab (Humira), сertolizumab pegol, golimumab were 111 536; 129 094; 85 244 RUR, consequently favour to tocilizumab. Tocilizumab was less costly comparing to adalimumab (Humira), certolizumab pegol, golimumab by 12.8, 14.5, 10,0 %, consequently. Cost minimizing ratio of tocilizumab in RA patients comparing to adalimumab (Dalibra), etanercept, infl iximab (Remicade) were 40 497; 54 355; 28 419 RUR in favour to comparators. Tocilizumab was more costly comparing to adalimumab (Dalibra) etanercept, infl iximab (Remicade) by 5.6; 7.7; 3.9 %, consequently. Cost minimizing ratio of tocilizumab in sJA patients comparing to kanakinumab, adalimumab (Humira) and adalimumab (Dalibra) were 6 535 234; 478 297 and 323 263 RUR. Tocilizumab was less costly comparing to kanakinumab, adalimumab (Humira) and adalimumab (Dalibra) by 93.3; 50.6 and 41.1 %, consequently. Conclusions. Tocilizumab is economically reasonable comparing to others TNF-α inhibitors in patients with RA and sJA.

rheumatoid arthritis, TNF-α inhibitors, healtheconomics

1. Клинические рекомендации Ревматоидный артрит, Ассоциация ревматологов России 2018 г. [Электронный ресурс]. [Klinicheskie rekomendacii Revmatoidnyj artrit, Associaciya revmatologov Rossii 2018 [Internet]. (In Russ).] Доступно по: http://cr.rosminzdrav.ru/#!/schema/173 Ссылка активна на 25.03.2020

2. Клинические рекомендации Юношеский артрит с системным началом, Союз педиатров России 2017 г. [Электронный ресурс]. [Klinicheskie rekomendacii YUnosheskij artrit s sistemnym nachalom, Soyuz pediatrov Rossii 2017 [Internet]. (In Russ).] Доступно по: http://www.pediatrrusia.ru/sites/default/fi les/fi le/kr_yuassn.pdf Ссылка активна на 25.03.2020

3. Государственный реестр предельных отпускных цен. [Gosudarstvennyj reestr predel’nyh otpusknyh cen. (In Russ).] Доступно по: http://grls.rosminzdrav.ru/pricelims.aspx Ссылка активна на 25.03.2020

4. Фарминдекс.РФ — Российский фармацевтический портал. [Электронный ресурс]. [Pharmindex.ru — Rossijskij farmacevticheskij portal. (In Russ).] Доступно по: https://www.pharmindex.ru Ссылка активна на 25.10.2019 г.

5. Alfonso-Cristancho R, Armstrong N, Arjunji R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clinical Rheumatology. 2017;36(1):25. DOI: 10.1007/s10067-016-3435-2

6. Synnott PG, Liu S, Agboola FO, Ollendorf D. Comparative efficacy of targeted immune modulators as mono-therapy and in combination with conventional DMARDs in rheumatoid arthritis. Value in Health. 20.5:A140-A141. Elsevier Ltd. (May 2017).

7. Tarp S, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016 Apr;55(4):669-679. DOI: 10.1093/rheumatology/kev382

8. Otten MH, et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis. 2013 Nov;72(11):1806-12. DOI: 10.1136/annrheumdis-2012-201991

9. Биологические препараты. Теравпевтические монклональные антитела с позиции клинической фармакологии. Колбин А.С. и др. — СПб.: ЦОП «Профессия»; 2019. — 80 с. [Biologicheskie preparaty. Teravpevticheskie monklonal’nye antitela s pozicii klinicheskoj farmakologii. Kolbin AS, et al. Saint-Petersburg: COP «Professiya»; 2019. (In Russ).]

10. Kim SC, et al. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019 Oct;49(2):222-228. DOI: 10.1016/j.semarthrit.2019.03.002

11. Pawar A, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 Apr;78(4):456-464. DOI: 10.1136/annrheumdis-2018-214367

12. Cantini F, et al. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-antitumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019 May;18(5):415-425. DOI: 10.1080/14740338.2019.1612872

13. Cantini F, et al. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. The Journal of Rheumatology Supplement. 2014 May;91:47-55. DOI: 10.3899/jrheum.140102

14. Распоряжение Комитета по здравоохранению Санкт-Петербурга от 30 мая 2017 года N 74-р «Об утверждении базовых нормативов затрат на оказание государственных услуг (выполнение работ) по противотуберкулезной медицинской помощи государственными автономными и бюджетными учреждениями здравоохранения Санкт-Петербурга на 2018 год и на плановый период 2019 и 2020 годов». [Order of the Committee on healthcare of Saint Petersburg of may 30, 2017 N 74-p «On approval of basic standards the cost of providing public services (works) for TB medical care and Autonomous state budget health care institutions of St. Petersburg in 2018 and the planning period of 2019 and 2020». (In Russ).] Доступно по: http://docs.cntd.ru/document/456071170 Ссылка активна на 25.03.2020

15. Калининская А.А., Горохова Т.А. Дневной стационар как механизм повышения эффективности использования коечного фонда во фтизиатрии // Электронный научный журнал «Социальные аспекты здоровья населения». 01.10.2011 г. [Электронный ресурс]. [Kalinskaya AA, Gorokhova TA. Day hospital as a tool to enhanced effi cacy of loading bed facility in phthisiology. Elektronnyj nauchnyj zhurnal «Social’nye aspekty zdorov’ya naseleniya». [Internet]. (In Russ).] [Internet]. 01.10.2011. Доступно по: http://vestnik.mednet.ru/content/view/320/30/ Ссылка активна на 25.10.2019 г.

16. Рудакова А.В. Фармакоэкономические аспекты применения биологических препаратов в терапии ревматоидного артрита // Медицинские технологии. Оценка и выбор. — 2012. — Т.8. — №2. — С.30-33. [Rudakova AV. Pharmacoeconomic aspects of biologic treatments for rheumatoid arthritis. Medicinskie tekhnologii. Ocenka i vybor. 2012;8(2):30-33. (In Russ).]

17. Горячев Д.В., Эрдес Ш.Ф, Насонов Е.Л. Фармакоэкономический анализ применения тоцилизумаба в терапии ревматоидного артрита. Имитационное моделирование // Научно-практическая ревматология. — 2010. — № 2. — С.87-102. [Goryachev DV, Erdes ShF, Nasonov EL. Pharmacoeconomic analysis of the use of tocilizumab in therapy for rheumatoid arthritis: Imitation simulation. Nauchno-prakticheskaya revmatologiya. 2010:(2);87-102. (In Russ).]